Overcoming drug resistance and treating advanced prostate cancer
about
Prostate Cancer Stem Cells: Research AdvancesERBB2 increases metastatic potentials specifically in androgen-insensitive prostate cancer cells.miR-195 Inhibits EMT by Targeting FGF2 in Prostate Cancer CellsMitochondrial dysfunction-mediated apoptosis resistance associates with defective heat shock protein response in African-American men with prostate cancer.Enzalutamide as a second generation antiandrogen for treatment of advanced prostate cancerThe marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer.Targeted suppression of AR-V7 using PIP5K1α inhibitor overcomes enzalutamide resistance in prostate cancer cells.Galectins as new prognostic markers and potential therapeutic targets for advanced prostate cancers.The hurdle of antiandrogen drug resistance: drug design strategies.Restoring TGFβ1 pathway-related microRNAs: possible impact in metastatic prostate cancer development.Octreotide in combination with AT-101 induces cytotoxicity and apoptosis through up-regulation of somatostatin receptors 2 and 5 in DU-145 prostate cancer cells.Oncolytic virus carrying shRNA targeting SATB1 inhibits prostate cancer growth and metastasis.Sunitinib reduces tumor hypoxia and angiogenesis, and radiosensitizes prostate cancer stem-like cells.Zoledronic acid increases cytotoxicity by inducing apoptosis in hormone and docetaxel-resistant prostate cancer cell lines.Tpl2 induces castration resistant prostate cancer progression and metastasis.Targeting integrin α6 stimulates curative-type bone metastasis lesions in a xenograft model.MiR-199a-3p suppresses proliferation and invasion of prostate cancer cells by targeting Smad1.Overexpression of MUC1 and Genomic Alterations in Its Network Associate with Prostate Cancer Progression.Immunohistochemical staining of ERG and SOX9 as potential biomarkers of docetaxel response in patients with metastatic castration-resistant prostate cancer.Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer.Histone Deacetylase (HDAC) Inhibitor, Suberoylanilide Hydroxamic Acid (SAHA), Induces Apoptosis in Prostate Cancer Cell Lines via the Akt/FOXO3a Signaling Pathway.Potent Inhibition of miR-34b on Migration and Invasion in Metastatic Prostate Cancer Cells by Regulating the TGF-β Pathway.APE1/Ref-1 redox-specific inhibition decreases survivin protein levels and induces cell cycle arrest in prostate cancer cells.Analysis of hematological parameters as prognostic markers for toxicity and survival of 223Radium treatment.The interplay between AR, EGF receptor and MMP-9 signaling pathways in invasive prostate cancer.Biphasic Alteration of Butyrylcholinesterase (BChE) During Prostate Cancer Development.Downregulation of IQGAP2 Correlates with Prostate Cancer Recurrence and MetastasisCancer Cells Exploit Notch Signaling to Redefine a Supportive Cytokine MilieuConstruction of a set of novel and robust gene expression signatures predicting prostate cancer recurrence
P2860
Q26998435-4023EAA0-6E4C-44E7-8272-95CFC4C10C9DQ33768865-30CE1B0A-5F7A-41AE-A934-FAE63BD69E58Q35864418-6CC8B565-26DD-49AD-A461-A9940B2956DBQ36898439-8B877998-A91C-4CDA-AF9F-E1FBED4171FFQ37146546-529D32B4-1E63-4292-950F-65C9C0C5C60BQ37520184-60B9F6E0-8BC5-4CCC-876B-1764264E85A5Q37665251-9711BDA7-EC91-44F8-896E-041710C5B8D0Q38160862-54E3E6E4-C247-445B-86BB-A80754DD8F6AQ38160927-53E225C8-31B5-4E42-A179-8AE5A4E9AC0DQ38206962-C6722280-91B0-4FCE-84D4-EB2862976CE6Q38822225-FB0676BF-1CD2-4FEE-919A-6A861B2E6B98Q38862880-DAEAA535-C57C-4FB1-B2FF-EAF18BDDB41DQ38884727-699AE1CF-8138-4C65-A38C-A5064B23E5DDQ38949883-B29748EC-60D7-43E8-B8E7-9F793E62CB0CQ38951496-6760DDE5-35F0-4C68-B26F-08CAFDFA75A9Q39003443-274367DB-4031-47FB-947A-81311767CA93Q41592757-F55E4E29-5046-414E-827A-4EBBCBBF96A6Q41667232-A04C2244-00C2-46E4-A7DD-24782E294DF5Q41839242-AF49BFE7-F956-49F4-BAD3-3AE0CCA079B1Q41866323-E0D611A3-15C0-4629-BED6-09050ED51354Q47324023-5A39DD56-BC22-49D9-81FE-2833C2CB5042Q49679082-BA06DFD6-A5F0-4622-A1B3-16B8799CDBDFQ51740038-21039937-E32F-4007-BE08-8FEDD65065E9Q55281053-CDAE5F73-9079-41A2-ADC4-BE209CB60952Q55425609-38D24361-63F7-407C-ABB5-C51181C0203CQ55518954-9268B33B-62CA-48AF-9E28-B9631AE440EEQ58695581-7EEEC8F4-7BD9-470D-B34F-0DCE80C4B2C6Q58781616-408D27EA-1E70-4D2F-9415-1F41D7485D9DQ58788279-A521A483-E2A5-4B51-BEF9-73D7646B68D8
P2860
Overcoming drug resistance and treating advanced prostate cancer
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Overcoming drug resistance and treating advanced prostate cancer
@ast
Overcoming drug resistance and treating advanced prostate cancer
@en
type
label
Overcoming drug resistance and treating advanced prostate cancer
@ast
Overcoming drug resistance and treating advanced prostate cancer
@en
prefLabel
Overcoming drug resistance and treating advanced prostate cancer
@ast
Overcoming drug resistance and treating advanced prostate cancer
@en
P2093
P2860
P50
P1433
P1476
Overcoming drug resistance and treating advanced prostate cancer
@en
P2093
Cinzia Allegrucci
Julius Semenas
Stephen A Boorjian
P2860
P304
P356
10.2174/138945012802429615
P5008
P577
2012-09-01T00:00:00Z